Loading...
•
Mar 31, 2023
Syndax Q1 2023 Earnings Report
Reported financial results for the quarter ended March 31, 2023 and provided a business update.
Key Takeaways
Syndax Pharmaceuticals reported its financial results for the quarter ended March 31, 2023. The company is expecting two U.S. registrational filings by the end of 2023. Topline data from the pivotal AGAVE-201 trial of axatilimab in cGVHD is on track for mid-2023, and topline data from the pivotal AUGMENT-101 trial of revumenib in KMT2Ar acute leukemia is on track for the third quarter of 2023.
Topline data from the pivotal AGAVE-201 trial of axatilimab in cGVHD is on track for mid-2023
Topline data from the pivotal AUGMENT-101 trial of revumenib in KMT2Ar acute leukemia is on track for the third quarter of 2023
Two U.S. registrational filings are expected by the end of 2023
The company expects research and development expenses to be $38 to $43 million and total operating expenses to be $53 to $58 million for the second quarter of 2023
Syndax
Syndax
Forward Guidance
The Company expects research and development expenses to be $38 to $43 million and total operating expenses to be $53 to $58 million for the second quarter of 2023. For the full year of 2023, the Company continues to expect research and development expenses to be $160 to $175 million and total operating expenses to be $225 to $240 million.